Clinical Trials Browser

Carcinoma, Endometrial Neoplasms

NCT00887380 2022-11-18

STARS

Phase 3 Unknown

2,023 enrolled

Breast

Breast Neoplasms

NCT05411380 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Phase 2 Unknown

73 enrolled

Breast

Breast Neoplasms

NCT05439499 2022-07-06

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Phase 3 Unknown

434 enrolled

Breast

Advanced Breast Cancer

NCT03966898 2021-06-02

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Phase 3 Unknown

426 enrolled

Breast

Advanced Breast Cancer

NCT00541086 2020-02-07

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Phase 3 Unknown

3,697 enrolled

Breast

Breast Neoplasms

NCT03024580 2019-08-15

MEGA

Phase 2 Unknown

20 enrolled

Breast

Breast Neoplasms

NCT04023292 2019-07-17

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Phase 2 Unknown

185 enrolled

Breast

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

Phase 2 Unknown

250 enrolled

Breast

Breast Diseases, Breast Neoplasms

NCT02689921 2018-09-28

NEOADAPT

Phase 2 Unknown

7 enrolled

Breast

Breast Neoplasms

NCT02910050 2017-12-22

BETTER

Phase 2 Unknown

58 enrolled

Breast

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT03211572 2017-07-07

OTT 17-01

Phase 2 Unknown

82 enrolled

Breast

Breast Neoplasms

NCT01266213 2017-05-01

FLAG

Phase 2 Unknown

147 enrolled

Breast

Breast Neoplasms

NCT02089854 2016-12-02

AETNBC

Phase 4 Unknown

800 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02097459 2016-05-25

Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

Phase 3 Unknown

600 enrolled

Breast

Breast Neoplasms

NCT01402193 2014-06-25

Study of Arimidex and Radiotherapy Sequencing

Phase 3 Unknown

220 enrolled

Breast

Breast Neoplasms, Camurati-Engelmann Syndrome

NCT02072512 2014-02-26

PROOF

Phase 2 Unknown

180 enrolled

Breast

Breast Neoplasms

NCT00688194 2013-08-26

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Phase 3 Unknown

396 enrolled

Breast

Breast Neoplasms

NCT01924078 2013-08-16

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Phase 2 Unknown

100 enrolled

Breast

Breast Neoplasms

NCT00398489 2010-11-09

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Phase 2 Unknown

94 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00687648 2009-06-17

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 2 Unknown

70 enrolled

Breast

Breast Neoplasms

NCT00902954 2009-05-15

LEANEX

Phase 3 Unknown

540 enrolled

Breast

Breast Neoplasms

NCT00077168 2009-02-09

Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole

Phase 2 Unknown

2,000 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Clinical Trials

VICTORIA

STARS

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

MEGA

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Pyrotinib

NEOADAPT

BETTER

OTT 17-01

FLAG

AETNBC

Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

Study of Arimidex and Radiotherapy Sequencing

PROOF

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

LEANEX

Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole